Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people diagnosed with breast cancer understand these risk factors. In recognizing the need for more education about breast cancer recurrence, Eli Lilly and Company launched a new education campaign in collaboration with Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G. Komen. This campaign aims to educate, support, connect, and empower people diagnosed with early breast cancer (EBC) that has a high risk of recurrence.
More than 290,650 women and 2,710 men are expected to be diagnosed with breast cancer in the US in 2022. Resources often describe early stage breast cancer as treatable and survivable. However, most people are at some risk of recurrence
